
Marc R Kok

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8327454/publications.pdf Version: 2024-02-01



MARC R KOK

#	Article	IF	CITATIONS
1	Etanercept in Sjögren's syndrome: A twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis and Rheumatism, 2004, 50, 2240-2245.	6.7	260
2	Local Adeno-Associated Virus-Mediated Interleukin 10 Gene Transfer Has Disease-Modifying Effects in a Murine Model of Sjögren's Syndrome. Human Gene Therapy, 2003, 14, 1605-1618.	1.4	191
3	Reengineered salivary glands are stable endogenous bioreactors for systemic gene therapeutics. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3053-3058.	3.3	92
4	Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. Atherosclerosis, 2013, 229, 174-181.	0.4	85
5	Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial. Rheumatology, 2019, 58, 1344-1352.	0.9	79
6	Salivary glands as a potential gene transfer target for gene therapeutics of some monogenetic endocrine disorders. Journal of Endocrinology, 2005, 185, 363-372.	1.2	69
7	Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial. Annals of the Rheumatic Diseases, 2022, 81, 925-936.	0.5	59
8	Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjögren's syndrome. Arthritis and Rheumatism, 2004, 51, 601-604.	6.7	50
9	Efficacy of Hydroxychloroquine in Hand Osteoarthritis: A Randomized, Doubleâ€Blind, Placebo ontrolled Trial. Arthritis Care and Research, 2018, 70, 1320-1325.	1.5	49
10	Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab — The GO-EASY Study. Journal of Rheumatology, 2019, 46, 153-159.	1.0	43
11	Re-engineering Primary Epithelial Cells from Rhesus Monkey Parotid Glands for Use in Developing an Artificial Salivary Gland. Tissue Engineering, 2006, 12, 2939-2948.	4.9	40
12	Cytometry by time of flight identifies distinct signatures in patients with systemic sclerosis, systemic lupus erythematosus and SjĶgrens syndrome. European Journal of Immunology, 2020, 50, 119-129.	1.6	39
13	The impact of gene therapy on dentistry. Journal of the American Dental Association, 2002, 133, 35-44.	0.7	35
14	Influence of Disease Manifestations on Health-related Quality of Life in Early Psoriatic Arthritis. Journal of Rheumatology, 2018, 45, 1526-1531.	1.0	34
15	Advances in vector-mediated gene transfer. Immunology Letters, 2003, 90, 145-149.	1.1	33
16	Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate. Annals of the Rheumatic Diseases, 2019, 78, 610-616.	0.5	33
17	Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis. Arthritis Care and Research, 2018, 70, 1764-1770.	1.5	29
18	Local expression of tumor necrosis factor-receptor 1:immunoglobulin G can induce salivary gland dysfunction in a murine model of SjĶgren's syndrome. Arthritis Research and Therapy, 2009, 11, R189.	1.6	26

Marc R Kok

#	Article	IF	CITATIONS
19	Immune responses following salivary gland administration of recombinant adeno-associated virus serotype 2 vectors. Journal of Gene Medicine, 2005, 7, 432-441.	1.4	24
20	Comparison of disease activity measures in early psoriatic arthritis in usual care. Rheumatology, 2019, 58, 2251-2259.	0.9	20
21	Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial. Lancet Rheumatology, The, 2019, 1, e145-e153.	2.2	19
22	Addressing Health Literacy Needs in Rheumatology: Which Patient Health Literacy Profiles Need the Attention of Health Professionals?. Arthritis Care and Research, 2021, 73, 100-109.	1.5	19
23	Impaired fertility in men diagnosed with inflammatory arthritis: results of a large multicentre study (iFAME-Fertility). Annals of the Rheumatic Diseases, 2021, 80, 1545-1552.	0.5	15
24	Induction of Inflammation and Fibrosis by Semaphorin 4A in Systemic Sclerosis. Arthritis and Rheumatology, 2019, 71, 1711-1722.	2.9	13
25	Vasodilator function worsens after cessation of tumour necrosis factor inhibitor therapy in patients with rheumatoid arthritis only if a flare occurs. Clinical Rheumatology, 2018, 37, 909-916.	1.0	12
26	Time to minimal disease activity in relation to quality of life, productivity, and radiographic damage 1Âyear after diagnosis in psoriatic arthritis. Arthritis Research and Therapy, 2019, 21, 25.	1.6	12
27	Single-Cell RNA Sequencing Reveals Heterogeneity and Functional Diversity of Lymphatic Endothelial Cells. International Journal of Molecular Sciences, 2021, 22, 11976.	1.8	9
28	Angiopoietin-2 Promotes Inflammatory Activation in Monocytes of Systemic Sclerosis Patients. International Journal of Molecular Sciences, 2020, 21, 9544.	1.8	8
29	Taking advances from bench to bedside during the last decade. Best Practice and Research in Clinical Rheumatology, 2012, 26, 225-236.	1.4	5
30	Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment. BMC Rheumatology, 2019, 3, 3.	0.6	4
31	Achieving sustained minimal disease activity with methotrexate in early interleukin 23-driven early psoriatic arthritis. RMD Open, 2020, 6, e001175.	1.8	4
32	Characterizing memory T helper cells in patients with psoriasis, subclinical, or early psoriatic arthritis using a machine learning algorithm. Arthritis Research and Therapy, 2022, 24, 28.	1.6	4
33	Paternal inflammatory arthritis is associated with a higher risk of miscarriage: results of a large multicentre study (iFAME-Fertility). Rheumatology, 2022, 61, 3390-3395.	0.9	4
34	Rituximab dose-dependent infection risk in rheumatoid arthritis is not mediated through circulating immunoglobulins, neutrophils or B cells. Rheumatology, 2022, 62, 330-334.	0.9	4
35	Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial. Arthritis Research and Therapy, 2019, 21, 208.	1.6	3
36	The burden of psoriasis in patients with early psoriatic arthritis. Rheumatology, 2022, 61, 1570-1578.	0.9	3

Marc R Kok

#	Article	IF	CITATIONS
37	Exploring discordance between Health Literacy Questionnaire scores of people with RMDs and assessment by treating health professionals. Rheumatology, 2022, 62, 52-64.	0.9	3
38	Remission of Incapacitating Acute Cutaneous Lupus Erythematosus in a Patient With Systemic Lupus Erythematosus by B Cell-Depletive Therapy. Journal of Clinical Rheumatology, 2010, 16, 345.	0.5	1
39	SAT0401â€USE OF AND RESPONSE TO METHOTREXATE IN EARLY PSORIATIC ARTHRITIS: RESULTS FROM THE R WORLD COHORT, DEPAR STUDY. , 2019, , .	EAL	1
40	Metaâ€Analyses on the Effects of Diseaseâ€Modifying Antirheumatic Drugs on the Most Relevant Patientâ€Reported Outcome Domains in Rheumatoid Arthritis. Arthritis Care and Research, 2023, 75, 1659-1672.	1.5	1
41	LB0010â€ULTRA-LOW DOSES OF RITUXIMAB OR RETREATMENT OF RHEUMATOID ARTHRITIS: A RANDOMISED CONTROLLED NON-INFERIORITY TRIAL. , 2019, , .		0
42	AB0395â€NO CLINICAL RELEVANT CHANGES IN EFFICACY, QUALITY OF LIFE AND TOLERABILITY FOR RA PATIEN IN CLINICAL REMISSION 16 WEEKS AFTER SWITCHING TO THE BIOSIMILAR IFX CT-P13 COMPARED TO THE ORIGINATOR; A DESCRIPTIVE REPORT. , 2019, , .	TS	0
43	Re-engineering Primary Epithelial Cells from Rhesus Monkey Parotid Glands for Use in Developing an Artificial Salivary Gland. Tissue Engineering, 2006, .	4.9	0